Zentalis Reports Q2 2026 Results, Cash Runway into Late 2027, and FDA Alignment on Accelerated Approval Path for Azenosertib

summarizeSummary

Zentalis reported Q2 2026 results with $174.6M in cash, runway into late 2027, and FDA alignment on an accelerated approval strategy for azenosertib. DENALI Part 2 enrollment is nearly complete, with topline data expected in 1H 2027.

check_boxKey Events · Earnings and Guidance · ZNTL

• Q2 2026 Financial Results

  Net loss of $42.3 million; cash, cash equivalents, and marketable securities of $174.6 million as of June 30, 2026, providing runway into late 2027.

• FDA Alignment on Accelerated Approval

  Type D meeting confirmed FDA has no objection to the 400mg QD 5:2 dose and DENALI Part 2 study population for potential accelerated approval in Cyclin E1-positive PROC.

• DENALI Part 2 Enrollment and Timeline

  Enrollment complete in Parts 2a and 2b; Part 2c enrolling. Integrated topline readout expected in 1H 2027 to allow data maturation.

• ASPENOVA Phase 3 Initiated

  First patient dosed in May 2026 in the confirmatory Phase 3 trial designed to support full approval.

auto_awesomeAnalysis · ZNTL · Life Sciences

Zentalis disclosed Q2 2026 financials with a net loss of $42.3 million and $174.6 million in cash, extending runway into late 2027. The FDA Type D meeting confirmed no objection to the selected dose and study population for potential accelerated approval of azenosertib in Cyclin E1-positive PROC. Enrollment in DENALI Part 2a and 2b is complete, with Part 2c enrolling, and topline data is expected in 1H 2027. The ASPENOVA confirmatory Phase 3 trial has dosed its first patient. These updates de-risk the regulatory path and provide a clear timeline to a pivotal catalyst, while the cash position supports operations through key milestones.